::::: COMPANY :::::

 :: MISSION ::

BioProtein Technologies is a biotechnology company specialized in the production of recombinant therapeutic proteins & vaccines in the milk of transgenic rabbits.

BioProtein Technologies is a Contract Manufacturing Organization (CMO). The Company provides pharmaceutical and biotechnology companies with fully integrated services from gene expression to industrial production of proteins and vaccines in milk.

Its proprietary technology offers customized packages supplying gram to dozens kilogram quantities of highly purified biopharmaceuticals with competitive advantages in terms of scale-up and time to market.

A strong expertise through the manufacturing process particularly in molecular and cellular biology, embryology, dairy science, and animal housing, allows the Company to successfully produce complex glycosylated proteins or vaccines in the milk of transgenic rabbits (e.g. monoclonal antibodies, plasma proteins, hormones, peptides and VLP-based multivalent vaccines.) --> More...

BioProtein Technologies has demonstrated its ability to meet the most rigorous specifications in protein production through recombinant proteins production programs, carried out in collaboration with several biotechnology companies or pharmaceutical companies. --> More…

:: HISTORY ::


BioProtein Technologies was founded by three scientists involved in transgenic animal and cloning research, Louis-Marie Houdebine, Jean-Paul Renard and Bernard Jégou, and an experienced manager from the business consultancy world, Marc Le Bozec. They shared the same view on the potential industrial applications of nearly 20 years of cutting-edge research in the field of gene expression and transgenic technology.
This view was soon backed by the top management of INRA, which provided the original core technology. ”BioProtein Technologies” was thus founded as a spin-off of INRA on July 1st 1998.
Since its founding, the Company raised a total of € 9.5 M with private investors and venture capital companies providing the Company with a solid visibility and stability to implement its plans. -- > More…

::::::::::::THE FOUNDERS

Marc Le Bozec //graduated from HEC//
He acquired proficiency in business management and in management of innovation especially within prestigious practices (Bossard Consultants – Gemini Consulting – and Arthur D. Little). Marc Le Bozec acted as CEO of BioProtein for 8 years prior to take new responsibilities as Chief Financial Officer for Cellectis.
Louis-Marie Houdebine //Ph.D, Chemical engineer//
He is director of the Animal Gene Study Laboratory at INRA (French National Agronomy Research Institute - Jouy-en-Josas, Yvelines – France). He is recognized worldwide as one of the leading specialists in the production of recombinant proteins in the milk of transgenic animals. He developed a pole of expertise in the field of vectors carrying genes.
Jean-Paul Renard //Ph.D., Engineer in agronomy//
He is director of the Reproduction and Developmental Biology Unit at INRA (Jouy-en-Josas, Yvelines – France). He is internationally recognized as one of the best specialists in the field of domestic animal cloning, particularly for pharmaceutical applications.
Bernard Jégou //Ph.D.//
He is director of the Animal Research Group for Male Reproduction at INSERM (French National Institute for Medical Research -Rennes University – France). He is carrying out ambitious projects in the field of spermatogenesis.
  François Deneux //graduated from ESSEC//
He is currently responsible for the healthcare practice of Arthur D. Little in France.
He has more than 20 years experience in strategy and management consulting especially within prestigious practices (Bossard Consultants – Gemini Consulting – and Arthur D. Little). He has been Managing Director of BioProtein Technologies from its creation in July 1998 up to May 2000.

::::::::: Back to TOP

  :: COLLABORATIONS ::

  :: INDUSTRIAL PARTNERSHIP ::

  

BioProtein Technologies has concluded manufacturing agreements with LFB (French Laboratory for Plasma Fractionation and Biotechnology) for feasibility studies regarding the production of recombinant proteins in the milk of transgenic rabbits.

  :: RESEARCH PARTNERSHIPS ::

  
BioProtein Technologies has a privileged partnership with INRA (the French National Institute for Agronomic Research).
INRA is one the most important research institutes in France; with a budget of € 520 M, 10.000 employees and a number of patents and breeders rights covering 500 marketed commercial crops.

This partnership provides BioProtein Technologies with:  
Know-how transfer, particularly in the fields of molecular biology, developmental biology and animal production.
Exclusive access to intellectual property: an exclusive licence for the production of proteins in milk.
Logistics support, laboratory and staff resources.

BioProtein Technologies has concluded agreements with top league laboratories or public research organizations:

INRA
Laboratory of Cellular and Molecular Biology (LM. Houdebine)
Laboratory of Developmental Biology (JP. Renard)
Laboratory of Gonadotropins Study of (F. Guillou)
Laboratory of Molecular Virology and Immunology (J. Cohen)

INSERM
Laboratory of Lipoprotein Biochemistry (L. Lagrost)

::::::::: Back to TOP

  :: RESOURCES ::
 JOUY-EN-JOSAS SITE (PARIS): RESEARCH & DEVELOPMENT
ADMINISTRATION, OPERATIONS & SALES The team is composed of 3 persons including 1 Chief Finance Officer, 1 Chief Operating Officer, 1 S&A secretary
MOLECULAR BIOLOGY 150 m² Laboratory: Research and development


EMBRYOLOGY




 200 m2 Laboratory: in charge of micro-injection and embryo transfer experiments. The team is made up of 2 scientists and 2 technicians.
PILOT HUSBANDRY 200 Rabbits Husbandry

 MAGNERAUD SITE (WEST FRANCE): HUSNBANDRY - MILKING
   
PILOT HUSBANDRY 400 Rabbits Husbandry. 2 husbandry technicians.

::::::::: Back to TOP

 :: PRODUCTION FACILITIES ::

:::::::: Animal Husbandry – Milking

BioProtein Technologies operates a state-of-the-art animal house currently accommodating up to 400 rabbits at the INRA site in Magneraud (West France).

These premises were designed by BioProtein Technologies in collaboration with INRA in order to meet US and European regulations. --> More…

The facilities include a confined milking room and a laboratory dedicated to the genetic analysis of newborn rabbits. Rabbits are mechanically milked using a milking machine designed in collaboration with INRA. This allows the efficient collection of 100 to 150 ml of milk per female per day of lactating period.

by courtesy of Grimaud Frères Selection

:::::::: Purification

The purification and analysis of proteins currently produced by BioProtein in milk is performed directly by its customers who generally have the know-how and infrastructure required.

For customers who should not have the required capabilities, BioProtein has developed partnerships with companies specializing in DSP, protein analysis and bio-safety testing.


 :: INVESTORS ::
FOUNDERS

GILDE (Netherlands)
CREAGRO (France)
IWIC (Luxembourg)

::::::::: Back to TOP